CARLSBAD, CA (December 7, 2020) – SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its Meridian ALIF (anterior lumbar interbody fusion) System and Reef A interbody with NanoMetalene® surface technology.
“SeaSpine has created one of the most comprehensive ALIF systems on the market that enables surgeons to address different pathological needs intraoperatively,” said Dr. Amrit Khalsa of Penn Presbyterian Medical Center in Philadelphia. “Having multiple anterior plate and no-profile standalone construct options available allows me to adjust on the fly, which is very beneficial when needed.”
The Meridian ALIF System with Reef A interbody is designed to provide maximum modularity with a wide array of constructs, either in standalone No-profile or TruProfile® configurations, along with robust fixation options, which collectively address a variety of different needs based on surgeon technique and clinical goals.
“Having used numerous ALIF systems over the past 20 years, I can say with confidence that the SeaSpine team has developed a system that encompasses every possible iteration of what a surgeon could need,” stated Dr. Carl Lauryssen of Central Texas Brain and Spine in Austin. “This system addresses simple to highly complex pathology. I can switch between a single screw or anchor, multiple screws or anchors, or a combination of both, at each level. A compelling aspect of this system is that it allows me to customize implant construct and manage operating room time more efficiently.”
The Reef A interbody portfolio features macro undercut structures and includes multiple footprints and lordotic options, allowing surgeons the ability to intraoperatively address specific anatomical patient needs.
“This next gen ALIF system is a culmination of our innovative modular system design, proprietary NanoMetalene surface technology and Reef Topography,” stated Dennis Cirino, Senior Vice President, Global Spinal Systems. “This expansion of our Fusion Engineered™ philosophy, when used with our market leading Orthobiologics, creates a best in class procedural solution.”
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the objectives of product design and the ability of the underlying products to achieve design objectives. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of clinical validation of products in limited commercial (or “alpha”) launch; unexpected delay, including as a result of developing and supporting the launch of new products, including as a result of obtaining regulatory clearances; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
# # #
Investor Relations Contact